Cann Global has teamed up with Western Sydney University’s NICM Health Research Institute to evaluate the efficacy of a unique strain of medicinal cannabis to slow the progression of Multiple Sclerosis (MS).

The proposed human clinical trials follow successful research undertaken for Cann Global at the Technion in Israel headed by Dr Dedi Meiri which identified a chemovar in a unique cannabis strain that both in vitro and in vivo (in mice trials) stopped the progression of MS, and in some cases significantly reversed the damage it caused.

NICM Health Research Institute has agreed to design a clinical trial protocol in consultation with Cann Global and clinical specialists in the field.

In addition to implementing the formal clinical trials, Cann Global intends to make the chemovar widely available to patients in Australia during 2021 via prescription under the special access scheme.

Join the Conversation

1 Comment

Your email address will not be published. Required fields are marked *

  1. I would love to be involved if I’m suitable for your trial. Is there an email address I can send you my details to?
    Many thanks
    Lucy
    (Living with remitting relapsing MS)